GP Pharm, S.A. の製品パイプライン分析2016

Global Markets Directが発行した調査報告書(DATA70209176)
◆英語タイトル:GP Pharm, S.A. - Product Pipeline Review - 2016
◆商品コード:DATA70209176
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年10月12日
◆ページ数:22
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

GP Pharm, S.A. – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘GP Pharm, S.A. – Product Pipeline Review – 2016’, provides an overview of the GP Pharm, S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GP Pharm, S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of GP Pharm, S.A.
- The report provides overview of GP Pharm, S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GP Pharm, S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GP Pharm, S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate GP Pharm, S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GP Pharm, S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GP Pharm, S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
GP Pharm, S.A. Snapshot 4
GP Pharm, S.A. Overview 4
Key Facts 4
GP Pharm, S.A. – Research and Development Overview 5
Key Therapeutic Areas 5
GP Pharm, S.A. – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
GP Pharm, S.A. – Pipeline Products Glance 9
GP Pharm, S.A. – Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
GP Pharm, S.A. – Drug Profiles 10
leuprolide acetate – Drug Profile 10
Product Description 10
Mechanism Of Action 10
R&D Progress 10
octreotide acetate MAR – Drug Profile 11
Product Description 11
Mechanism Of Action 11
R&D Progress 11
Pegylated Doxorubicin – Drug Profile 12
Product Description 12
Mechanism Of Action 12
R&D Progress 12
risperidone depot – Drug Profile 13
Product Description 13
Mechanism Of Action 13
R&D Progress 13
GP Pharm, S.A. – Pipeline Analysis 14
GP Pharm, S.A. – Pipeline Products by Target 14
GP Pharm, S.A. – Pipeline Products by Route of Administration 15
GP Pharm, S.A. – Pipeline Products by Molecule Type 16
GP Pharm, S.A. – Pipeline Products by Mechanism of Action 17
GP Pharm, S.A. – Dormant Projects 18
GP Pharm, S.A. – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 21
Disclaimer 22

List of Tables
GP Pharm, S.A., Key Facts 4
GP Pharm, S.A. - Pipeline by Indication, 2016 6
GP Pharm, S.A. - Pipeline by Stage of Development, 2016 7
GP Pharm, S.A. - Monotherapy Products in Pipeline, 2016 8
GP Pharm, S.A. - Preclinical, 2016 9
GP Pharm, S.A. - Pipeline by Target, 2016 14
GP Pharm, S.A. - Pipeline by Route of Administration, 2016 15
GP Pharm, S.A. - Pipeline by Molecule Type, 2016 16
GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2016 17
GP Pharm, S.A. - Dormant Developmental Projects,2016 18
GP Pharm, S.A., Other Locations 20

List of Figures
GP Pharm, S.A. - Pipeline by Indication, 2016 6
GP Pharm, S.A. - Pipeline by Target, 2016 14
GP Pharm, S.A. - Pipeline by Route of Administration, 2016 15
GP Pharm, S.A. - Pipeline by Molecule Type, 2016 16
GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2016 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GP Pharm, S.A. の製品パイプライン分析2016(GP Pharm, S.A. - Product Pipeline Review - 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆